VPI-ETHACRYNATE SODIUM POWDER FOR SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ETHACRYNIC ACID (ETHACRYNATE SODIUM)

から入手可能:

VPI PHARMACEUTICALS INC

ATCコード:

C03CC01

INN（国際名）:

ETACRYNIC ACID

投薬量:

50MG

医薬品形態:

POWDER FOR SOLUTION

構図:

ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

LOOP DIURETICS

製品概要:

Active ingredient group (AIG) number: 0101703001; AHFS:

認証ステータス:

APPROVED

承認日:

2017-03-10

製品の特徴

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ETHACRYNATE SODIUM
(Ethacrynate sodium for injection, USP)
Lyophilized powder for injection, 50 mg equivalent to ethacrynic acid
STERILE
Saluretic-Diuretic
Agent
SteriMax Inc.
2770 Portland Drive,
Oakville, ON L6H 6R4.
Date of Preparation:
FEB 28, 2024
Submission Control No: 283328
_Product Monograph ETHACRYNATE SODIUM _
_Page 2 of 19_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
...................................................................................................
7
DOSAGE AND ADMINISTRATION
...............................................................................
8
OVERDOSAGE
.................................................................................................................
9
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 9
STORAGE AND STABILITY
.........................................................................................
10
SPECIAL HANDLING INSTRUCTIONS
......................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 10
PART II: SCIENTIFIC INFORMATION
...............................................................................
11
PHARMACEUTICAL INFORMATION
......................................................................